193 related articles for article (PubMed ID: 26582563)
41. Resveratrol ameliorates imiquimod-induced psoriasis-like skin inflammation in mice.
Kjær TN; Thorsen K; Jessen N; Stenderup K; Pedersen SB
PLoS One; 2015; 10(5):e0126599. PubMed ID: 25965695
[TBL] [Abstract][Full Text] [Related]
42. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases.
Froidevaux S; Calame-Christe M; Schuhmacher J; Tanner H; Saffrich R; Henze M; Eberle AN
J Nucl Med; 2004 Jan; 45(1):116-23. PubMed ID: 14734683
[TBL] [Abstract][Full Text] [Related]
43. Comparative anti-psoriatic efficacy studies of clobetasol loaded chitin nanogel and marketed cream.
Panonnummal R; Jayakumar R; Sabitha M
Eur J Pharm Sci; 2017 Jan; 96():193-206. PubMed ID: 27615594
[TBL] [Abstract][Full Text] [Related]
44. Possibilities of the microemulsion use as indomethacin solubilizer and its effect on
Špaglová M; Čuchorová M; Šimunková V; Matúšová D; Čierna M; Starýchová L; Bauerová K
Drug Dev Ind Pharm; 2020 Sep; 46(9):1468-1476. PubMed ID: 32715801
[TBL] [Abstract][Full Text] [Related]
45. alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma?
Kokot A; Sindrilaru A; Schiller M; Sunderkötter C; Kerkhoff C; Eckes B; Scharffetter-Kochanek K; Luger TA; Böhm M
Arthritis Rheum; 2009 Feb; 60(2):592-603. PubMed ID: 19180474
[TBL] [Abstract][Full Text] [Related]
46. A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation.
Avasatthi V; Pawar H; Dora CP; Bansod P; Gill MS; Suresh S
Pharm Dev Technol; 2016 Aug; 21(5):554-62. PubMed ID: 26024238
[TBL] [Abstract][Full Text] [Related]
47. Mechanical properties, skin permeation and in vivo evaluations of dexibuprofen-loaded emulsion gel for topical delivery.
Jin SG; Yousaf AM; Son MW; Jang SW; Kim DW; Kim JO; Yong CS; Kim JH; Choi HG
Arch Pharm Res; 2015 Feb; 38(2):216-22. PubMed ID: 24988989
[TBL] [Abstract][Full Text] [Related]
48. Percutaneous delivery of econazole using microemulsion as vehicle: formulation, evaluation and vesicle-skin interaction.
Ge S; Lin Y; Lu H; Li Q; He J; Chen B; Wu C; Xu Y
Int J Pharm; 2014 Apr; 465(1-2):120-31. PubMed ID: 24530389
[TBL] [Abstract][Full Text] [Related]
49. Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore.
Brzoska T; Böhm M; Lügering A; Loser K; Luger TA
Adv Exp Med Biol; 2010; 681():107-16. PubMed ID: 21222263
[TBL] [Abstract][Full Text] [Related]
50. Formulation and ex vivo evaluation of rofecoxib gel for topical application.
Das MK; Ahmed AB
Acta Pol Pharm; 2007; 64(5):461-7. PubMed ID: 18540168
[TBL] [Abstract][Full Text] [Related]
51. Enhancing percutaneous delivery of methotrexate using different types of surfactants.
Javadzadeh Y; Hamishehkar H
Colloids Surf B Biointerfaces; 2011 Feb; 82(2):422-6. PubMed ID: 20951009
[TBL] [Abstract][Full Text] [Related]
52. Roles of the melanocortin-4 receptor in antipyretic and hyperthermic actions of centrally administered alpha-MSH.
Sinha PS; Schiöth HB; Tatro JB
Brain Res; 2004 Mar; 1001(1-2):150-8. PubMed ID: 14972664
[TBL] [Abstract][Full Text] [Related]
53. Dopamine release in the lateral hypothalamus is stimulated by α-MSH in both the anticipatory and consummatory phases of feeding.
Legrand R; Lucas N; Breton J; Déchelotte P; Fetissov SO
Psychoneuroendocrinology; 2015 Jun; 56():79-87. PubMed ID: 25805178
[TBL] [Abstract][Full Text] [Related]
54. Improved cutaneous wound healing after intraperitoneal injection of alpha-melanocyte-stimulating hormone.
de Souza KS; Cantaruti TA; Azevedo GM; Galdino DA; Rodrigues CM; Costa RA; Vaz NM; Carvalho CR
Exp Dermatol; 2015 Mar; 24(3):198-203. PubMed ID: 25431356
[TBL] [Abstract][Full Text] [Related]
55. Loading of water-insoluble celastrol into niosome hydrogels for improved topical permeation and anti-psoriasis activity.
Meng S; Sun L; Wang L; Lin Z; Liu Z; Xi L; Wang Z; Zheng Y
Colloids Surf B Biointerfaces; 2019 Oct; 182():110352. PubMed ID: 31306831
[TBL] [Abstract][Full Text] [Related]
56. alpha-MSH and gamma-MSH inhibit IL-1beta induced activation of the hypothalamic-pituitary-adrenal axis through central melanocortin receptors.
Cragnolini AB; Perelló M; Schiöth HB; Scimonelli TN
Regul Pept; 2004 Nov; 122(3):185-90. PubMed ID: 15491790
[TBL] [Abstract][Full Text] [Related]
57. Melanoma targeting with DOTA-alpha-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake.
Froidevaux S; Calame-Christe M; Tanner H; Eberle AN
J Nucl Med; 2005 May; 46(5):887-95. PubMed ID: 15872364
[TBL] [Abstract][Full Text] [Related]
58. In vitro and in vivo evaluation of topical formulations of spantide II.
Kikwai L; Babu RJ; Prado R; Kolot A; Armstrong CA; Ansel JC; Singh M
AAPS PharmSciTech; 2005 Oct; 6(4):E565-72. PubMed ID: 16408858
[TBL] [Abstract][Full Text] [Related]
59. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis.
Lapteva M; Mondon K; Möller M; Gurny R; Kalia YN
Mol Pharm; 2014 Sep; 11(9):2989-3001. PubMed ID: 25057896
[TBL] [Abstract][Full Text] [Related]
60. Alpha-melanocyte-stimulating hormone through melanocortin-4 receptor inhibits nitric oxide synthase and cyclooxygenase expression in the hypothalamus of male rats.
Caruso C; Mohn C; Karara AL; Rettori V; Watanobe H; Schiöth HB; Seilicovich A; Lasaga M
Neuroendocrinology; 2004; 79(5):278-86. PubMed ID: 15218320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
